Category - Markets

Leerink resumed coverage of T2 Biosystems (NASDAQ:TTOO) with a “market perform” rating and $5 price target. The stock finished at $6.31 on Wednesday. “While we view T2’s proprietary T2MR pathogen detection technology...

Leerink resumed coverage of Invitae (NASDAQ:NVTA) with an “outperform” rating and $12 price target. The stock closed at $8.44 on Wednesday. Analyst Puneet Souda writes that Invitae is a high growth, commercial-stage...

Roth Capital Partners upgraded Applied Genetic Technologies (NASDAQ:AGTC) to “buy” from “neutral” and raised its price target to $15 from $12. The stock jumped $2.15 to $9.20 in afternoon trading on Wednesday. “With...

Maxim Group upgraded Keryx Biopharmaceuticals (NASDAQ:KERX) to “buy” from “hold” and reinstated its $7 price target after the FDA approved its application for a second contract manufacturer of Auryxia for the control of...

Closely-held CorWave has completed a $17.1-million Series B financing with existing shareholders, including Sofinnova Partners, Bpifrance and Seventure, and two new investors: Novo Seeds, which led the round, and Ysios...

Stifel downgraded Tandem Diabetes (NASDAQ:TNDM) to “hold” from “buy” and slashed its price target to $3.50 from $15 after a more disappointing than expected third quarter earnings performance and now sharply lower...

Roth Capital Partners initiated coverage of Global Blood Therapeutics (NASDAQ:GBT) as a “Focus Pick” with a “buy” rating and price target of $47. The stock closed at $17.45 on Monday “In our view, Global Blood...

Mackie Research launched coverage of Aurinia Pharmaceuticals (NASDAQ:AUPH) with a “speculative buy” recommendation and a 12-month target price of $8. The stock closed at $3.03 on Monday. Aurinia is developing...

Ladenburg Thalmann initiated coverage of Kindred Biosciences (NASDAQ:KIN) with a “buy” rating and a $7.50 price target. The stock closed at $5.40 on Monday. “We view Kindred as an emerging leader in development of new...

Echelon Wealth Partners raised its price target for RepliCel Life Sciences (TSX-V:RP) to $2.15 from $1.50 after the company closed a unit offering that will add about $4.1-million in net cash to its balance sheet. The...